Cancer Drugs · global
Ris-Rez shows 61% response rate in early global trial; efficacy and toxicity in small cell lung cancer remain to be weighed
Following reports of a survival benefit in a phase 3 trial in China, the first global trial data for this B7-H3 antibody-drug conjugate show confirmed responses in 11 of 18 evaluable patients in the higher-dose group. However, greater toxicity and limited follow-up leave the durability of efficacy as the next test.
For patients with relapsed extensive-stage small cell lung cancer, the treatment challenge is not just shrinking tumors, but also how long that effect lasts and whether the body can tolerate treatment. GSK announced on October 18 that its experimental drug risvutatug rezetecan (Ris-Rez) achieved a confirmed objective response rate of 61% in the higher-dose group of an early global trial. The result adds clinical evidence beyond the phase 3 trial in China, but cannot yet answer whether patients globally will live longer as a result.
The newly released findings are from the phase 1b dose-optimization portion of the EMBOLD PanTumour-101 trial. According to GSK's announcement and an RNS regulatory announcement published the following day, 50 patients with relapsed disease were randomly assigned to receive Ris-Rez at 6 or 8 milligrams per kilogram of body weight, administered intravenously every three weeks. Patients had received a median of two prior treatments. The open-label study compared two doses of the same drug and had no standard-treatment control group.
Among patients evaluable for efficacy, 11 of 18 in the 8-milligram group achieved a confirmed response, approximately 61%, compared with 7 of 22 in the 6-milligram group, approximately 32%. An objective response means that tumors shrink or disappear according to assessment criteria; it does not mean a cure. The 95% confidence intervals for the two response rates were 35.7% to 82.7% and 13.9% to 54.9%, respectively. These ranges are wide and overlap, so the numerical advantage at the higher dose cannot yet be considered an established difference in efficacy.
Dose selection also involves safety trade-offs. Grade 3 or higher treatment-related adverse events occurred in 42% of patients in the 8-milligram group and 15% in the 6-milligram group, with hematologic events the most common. Among all 50 patients, one also developed grade 2 interstitial lung disease. GSK described the overall safety profile as manageable, but median follow-up was only 100.5 days, still insufficient to fully characterize the risks of longer-term treatment.
Ris-Rez is an antibody-drug conjugate (ADC) that targets the B7-H3 protein, using an antibody to recognize the target and carry a cytotoxic drug. At the data cutoff, enrollment in the dose-optimization portion was ongoing. The efficacy analysis also covered only 40 evaluable patients, rather than all 50. How long responses last, the outcomes of patients excluded from the efficacy assessment, and disease progression and survival results are all essential questions when interpreting the 61% figure.
Background
Hansoh's earlier phase 3 ARTEMIS-008 trial in China had already reported an improvement in overall survival. The global phase 1b data now provide early information on activity and dosing in a different study population. Dow Jones Newswires' reporting also clearly distinguished between the two trials. GSK said the two studies together support using 8 milligrams per kilogram in the global phase 3 EMBOLD SCLC-301 trial, which must still test the clinical benefit of this dose.
According to Dow Jones, GSK is advancing late-stage trials in lung and prostate cancer and is also planning studies in earlier lines of treatment. However, the pace of development cannot replace mature follow-up data. For relapsed small cell lung cancer, these results provide a reason for further testing. What ultimately determines the treatment's value will be whether tumor control is durable and whether the benefits outweigh the toxicity.